Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE AND PRILOCAINE versus ROPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE AND PRILOCAINE versus ROPIVACAINE HYDROCHLORIDE.
LIDOCAINE AND PRILOCAINE vs ROPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine and prilocaine are amide-type local anesthetics that stabilize neuronal membranes by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
Apply 2.5 g cream (lidocaine 25 mg/prilocaine 25 mg) to intact skin under occlusive dressing; maximum single application area 400 cm², maximum application time 4 hours. For genital mucous membranes: apply 5-10 g for 5-10 minutes without occlusion. Not recommended for dental use.
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
None Documented
None Documented
Lidocaine: 1.5-2 hours; prilocaine: 1.5-2 hours. In hepatic impairment, half-life may be prolonged up to 2-3 times.
Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance.
Renal excretion of metabolites (lidocaine: 70-80% as 4-hydroxy-2,6-xylidine and conjugates; prilocaine: 85-95% as o-toluidine metabolites and conjugates). Less than 10% of parent drugs excreted unchanged.
Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor.
Category A/B
Category A/B
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic